SGS invests €3.5m in its French bioanalytical site

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/Benedetta Barbanti / EyeEm)
(Image: Getty/Benedetta Barbanti / EyeEm)

Related tags: Bioanalytical, Small molecule, Small molecule drugs, Biologics, expansion, facility, Contract manufacturing

This second phase of the two-phase expansion project will increase the company’s bioanalytical capabilities at the site by 50% when the expansion is complete in 2020.

SGS’s facility in Poitiers, France offers contract bioanalytical services for both small molecules and biologics. The services extend to include mass spectrometry, immunoassays, and cell-based assays.

The first phase of the project was completed in November of this year. It saw the addition of a 150 square meter immunoassay laboratory and the capacity to employ 20 analysts.

Now, the next phase will begin with a new 800 square meter building which will house a new laboratory and office space. The renovation of the existing laboratory on site will also occur at this time.

The €3.5m ($3.9m) expansion project will also see a new electronic laboratory notebook system introduced across the entire facility in addition to an upgraded site quality management system and sample automation capabilities.

Over the past two years, the company has increased its staff recruitment by more than 25% and will continue to recruit and accelerate employment through Q3 2019.

SGS has 18 laboratories all of which offer contract analytical and bioanalytical services. SGS also provides Phase I-IV clinical trial management, and data management and statistics services.

The site expansion follows an investment and expansion​ of services at SGS’ site at its Lincolnshire, IL​, Geneva and Mississauga, Canada​ laboratories. 

Related news

Show more

Related products

show more

Stability Testing As a Quality Control Measure

Stability Testing As a Quality Control Measure

Frontage Laboratories | 19-Jun-2019 | Technical / White Paper

Stability testing is, in essence, a quality control process and is there¬fore a vital component of every phase of clinical development for both large and...

Leveraging Best Practices in Primary Packaging

Leveraging Best Practices in Primary Packaging

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

When planning a clinical trial, overlooking the importance of primary packaging can be a mistake. From stability concerns to labeling to patient compliance...


Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers

Follow us


View more